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An increasing body of experimental evidence (1) supports the concept that subsets 
of T  lymphocytes that suppress humoral and cell-mediated immune responses partic- 
ipate in a defined pathway that is governed by complimentary receptor-antireceptor 
interactions. Cells at various stages of this pathway can be distinguished by surface 
phenotype, specificity, and functional effects. The earliest evidence supporting this 
notion came from the studies of Eardley et al. (2), who showed that Lyt-1  +2- cells act 
on Lyt-l+2  + precursors and  trigger them  to mature  into potent suppressor T  cells 
(Ts).  More  recent  experiments  analyzing  suppression  of delayed  hypersensitivity 
responses to the haptens, azobenzenearsonate (ABA), and nitrophenyl, indicate that 
antigen-reactive Ts (termed Tsl) induce second-order anti-idiotypic Ts2, which sup- 
press the hapten-specific immune response, probably by inducing or functioning in 
concert with a third, antigen-specific cell termed Ts3 (3, 4). 
To define the mechanisms of action of Ts, we and others have attempted to develop 
clonal  systems  in  which  homogeneous  neoplastic  cells  can  be  used  as  targets  of 
immunoregulatory stimuli. In particular, we have shown that  irnmunoglobulin  (Ig) 
secretion by the  BALB/c myeloma, MOPC  315  (IgA, ~2,  specific for 2,4,-dinitro- 
phenyl and  2,4,6-trinitrophenyl), can be inhibited by culturing these cells with Ts, 
specific for the M315 idiotype (5). This phenomenon is especially intriguing because 
the inhibition of Ig secretion is selective, in that membrane receptor expression is not 
blocked (5), and, in a somatic cell hybrid line that secretes two idiotypically unrelated 
Ig, Ts, specific for each idiotype, block secretion of only that Ig (6).  In addition, Ts 
induced  by  immunizing  BALB/c  mice  with  the  M315  IgA  have  been  shown  to 
suppress IgA secretion and synthesis by MOPC 315 cells in vivo and in vitro without 
affecting receptor expression or the synthesis of non-Ig protein (7, 8). Two features of 
our  results  that  were  observed  consistently  were  that  significant  suppression  of 
myeloma cell function required 3-4 d co-culture of MOPC 315 cells and Ts, and the 
maximum inhibition was 40-70% by hemolytic plaque assays (5, 6). Because of these 
findings, biochemical analysis of myeloma suppression was difficult. Since we induced 
Ts by intravenous immunization with M315 IgA-coupled syngeneic splenocytes, we 
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reasoned  that  these cells corresponded to Tsa and needed  to differentiate  further  in 
vitro to develop into effector Ts (3, 4). We report our attempts to generate effector Ts 
using a protocol that was first established in studies of the suppression of ABA-specific 
immunity.  In principle,  this  protocol involves immunization  of mice with  a  soluble 
extract of Tsa cells and subcutaneous priming with antigen- (or, in the present system, 
M315 IgA-) modified splenoeytes (3). Our results indicate that it is possible to generate 
effector Ts reactive with myeloma idiotypes and that such Ts differ from Tsl  in the 
kinetics of their effect and in surface phenotype. 
Materials  and Methods 
Induction of Suppressor T Cells.  BALB/c mice (12-16 wk of age, purchased from Cumberland 
Farms, Clinton, TN) were injected intravenously with 5-10 ×  107 viable syngeneie splenocytes 
to which affinity-purified M315 IgA was coupled, using the covalent coupling reagent  1-ethyl 
3-(3-diaminopropyl) carhodiimide, as described previously (5). Spleen cells were removed 6 or 
7 d later and were depleted of erythrocytes by treatment with Tris-buffered 0.83% NH4CI. B 
lymphocytes were removed by binding to dishes coated with affinity-purified rabbit anti-mouse 
Ig (9); such preparations routinely contained <2% surface Ig-bearing cells by immunofluores- 
cence  and  showed  a  >90%  depletion  of lipopolysaccharide  responsiveness.  These  cells  are 
referred to as Tsl. Soluble extracts of Tsl cells (TsF1) were prepared by four cycles of freezing 
and thawing and centrifugation at 12,000 g for removing cellular debris. To induce effector Ts, 
BALB/c mice were immunized subcutaneously with 3 ×  107 viable M315 IgA-coupled syngeneic 
.......  7  splenocytes at two sites on the flank and were g~ven dally intravenous rejections of 2 ×  10  cell 
equivalents of TsF1 for the next 5 d. Spleen cells were removed 1 d later, and T  lymphocytes 
were prepared as for Tsl. 
Myeloma  Cell  Cultures and  Assays.  These  techniques  have  been  described  previously  (15) 
Briefly,  tissue culture-adapted MOPC 315 cells were centrifuged over Ficoll-Isopaque, and ,v 
viable myeloma cells were cultured with varying numbers of T  lymphocytes in flat-bottomed 
96-well Linbro wells (Flow Laboratories, McLean, VA) in triplicate. Cultures were done in 0.2 
ml of RPMI 1640 supplemented with 2 mM L-glutamine, penicillin, streptomycin, nonessential 
amino acids, 5 ×  10-  M  2-mercaptoethanol,  and  10% heat-inactivated fetal calf serum  (all 
from Gibco Laboratories, Grand  Island Biological Co.,  Grand  Island,  NY)  in a  humidified 
atmosphere  of 5%  CO2.  At  the end  of culture,  the cells  were harvested,  washed  once, and 
aliquots were used  to  (a)  measure  viable myeloma cell  recovery, viability being assessed  by 
trypan blue dye exclusion, and  (b) determine the numbers of IgA-seereting cells by a reverse 
hemolytic plaque assay using Staphylococcus protein A-coated sheep erythrocytes as indicator 
cells (5). Results are expressed as IgA plaque-forming cells (PFC) per 103 viable myeloma cells 
recovered, and statistical analyses were done by Student's t tests. 
Other Techniques.  For depletion of various T cell subsets,  aliquots of cells were treated with 
monoclonal anti-Thy-1.2, anti-Lyt-1.2, or anti-Lyt-2.2 antibody (New England Nuclear, Boston, 
MA) in serum-free L-15 for 40 min at room temperature. After one wash, the cells were treated 
with  1:8-1:10 dilution of low-tox rabbit complement (Cedarlane Laboratories, Hornby, On- 
tario, Canada) in L-15 for 45 min at 37°C, and viable cell recovery was determined after three 
washes.  Dish binding experiments were done as previously described (5, 6), using plastic dishes 
coated with various myeloma Ig to deplete T cells of appropriate specificities. 
Results  and  Discussion 
Previous experiments  had established  that M315-specific Tsx, induced by intrave- 
nous immunization with M315-coupled spleen cells, suppressed  IgA secretion by the 
MOPC  315 myeloma after 3-4 d  of co-culture  (5).  In the first series of experiments, 
we compared ttie kinetics of suppression  induced by culturing MOPC  315 cells with 
TSl and T  cells  generated  by subcutaneous  immunization  with  M315-coupled sple- 
nocytes, together with administration  of TsFa. The pooled data illustrated  in Fig.  1 
show  that  Tsa  produce  significant  inhibition  of IgA PFC  after  >2  d  culture  with 1218  ABBAS ET AL.  BRIEF  DEFINITIVE REPORT 
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FIG.  1.  10  s MOPC 315 cells were cultured alone (O), or with  10  e (A) or 2 X 10  e (B) splenic T 
lymphocytes from normal BALB/c mice (ll), or with mice immunized as follows:  O, 3 ×  10  7 M315- 
coupled splenocytes s.c.; I-1, TsF1 for 5 d i.v.; O, 5 X  107 tO 10 X 10  7 M315-coupled splenocytes i.v. 
(Tsl); and &, 3 ×  10  7  M315-coupled splenocytes s.c. plus TsFI for 5 d i.v. (effector Ts). IgA PFC 
were measured by reverse hemolytic plaque assays 1, 2, and 4 d after culture initiation. Groups 
showing statistically significant suppression (P <  0.01 'compared to  MOPC 315 cells alone by 
Student's t tests) are marked with asterisks. Data are pooled from four experiments. 
MOPC  315 cells, whereas T  cells induced by TsF1 and subcutaneous  immunization 
suppress >50% of the PFC within  1 d and 80-90% by 4 d. T  lymphocytes from normal 
BALB/c mice, or mice immunized only with M315-coupled cells subcutaneously, or 
TsF  were  not  significantly  suppressive.  We  have  operationally  termed  the  cells 
mediating  rapid  suppression  (i.e.,  within  1 d)  "effector Ts."  By analogy with  other 
systems  (3),  it  can be predicted  that  M315-specific TsFI induces a  second-order Ts2 
whose specificity  is  anti-(anti-M315),  and  subcutaneous  immunization  with  M315- 
coupled cells leads to the generation of the effector Ts  (Ts3).  However, we have not 
yet been able to demonstrate the existence of Ts2 in the MOPC  315 system because 
of the lack of a definitive marker for specificity. Moreover, it has not been possible to 
generate  effector Ts  by  in  vitro  culture  of Tsl,  as  has  been  done  for  nitrophenyl- 
reactive Ts (4). 
The specificity of the effector Ts was assessed by their ability to bind to different 
myeloma  proteins.  As  shown  in  Table  I,  suppressive  activity  can  be  depleted  by 
absorbing effector Ts on dishes coated with M315 IgA but not on dishes coated with 
MPCll  (IgG2b,k of unknown  specificity)  or M460  proteins.  MOPC  460  secretes  an 
IgA, k antibody that has the same specificity for dinitrophenyl and trinitrophenyl  as 
MOPC  315  but  has  largely  dissimilar  idiotypic  determinants  (10).  Furthermore, 
M315-specific  effector  Ts  do  not  inhibit  MPC  11  cells  and  cause  >70%  selective 
suppression  of IgA secretion  by the  MOPC  315-MPCll  somatic  cell  hybrid.  This 
selective effect is observed with hemolytic plaque assays as well as gel electrophoretic 
analysis ofimmunoprecipitated Ig produced by the somatic cell hybrid (G. Moser, M. 
Takoaki, I. Fox, M. I. Greene, and A. K. Abbas, manuscript  in preparation). 
Finally,  antibody and complement  treatment  of suppressor cells showed that  the 
effector Ts are Thy-l.2 +, Lyt-1-2  + cells (Table II). In contrast, the suppressive effect 
of Tsl can be abrogated by treating the cells with either anti-Lyt- 1 plus complement 
or anti-Lyt-2 plus complement, indicating that these cells are either Lyt-l+2  + or that 
T  lymphocytes bearing  both  Lyt-1 ÷  and  Lyt-2  +  markers  are  necessary  for Tsa  to 
induce or mature into effector Ts in vitro (2). ABBAS  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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IgA PFC/ 
Experi-  T  lymphocytes  Days of  10  a MOP(3  P* 
ment  culture 
315 cells 
mean  ~  SE 
1  None  1  209 :t: 4  -- 
Normal BALB/c, 2 ×  106  1  177 _+ 29  NS:~ 
Effector Ts, 2 X  10  s  1  133 ±  21  <0.005 
Effeetor  Ts, depleted  on  M315-coated  1  195 ::1:13  NS 
dish, 2 X  10  n 
Effector  Ts, depleted on  M460-coated  1  87 ±  19  <0.001 
dish, 2 ×  10  n 
None  2  209 ±  10  -- 
Effector  "is, 106  2  96 -e 20  <0,005 
Effector Ts, 2 X  106  2  61 zl: 10  <0.001 
Effector  Ts, depleted on M315-coated  2  288 ~  31  NS 
dish, 106 
Effector  Ts, depleted on  M315-coated  2  216 __. 36  NS 
dish, 2 ×  10  s 
Effector  Ts, depleted  on  M46~coated  2  85 zt: 23  <0.001 
dish, l0  s 
Effector  Ts, depleted on  M460-coated  2  81 +_ 11  <0.001 
dish, 2 X  106 
2  None  2  288 ::!:  6  -- 
Effeetor  Ts,  depleted  on  M315-coated  2  256 :i: 30  NS 
dish, 2 X  106 
Effector  Ts, depleted on  MPCII  IgG-  2  63 "Jr 3  <0.001 
coated dish, 2 X  10  n 
10  s  MOP(3  315  cells  were cultured  in  triplicate  with  splenic  T  lymphocytes  from  normal 
BALB/c mice or mice immunized to generate effector Ts. The Ts were untreated or depleted on 
myeloma protein-coated dishes, as described  in Materials and Methods. lEA PFC were measured 
by reverse hemolytic plaque assays.  Data from two representative  experiments out of four are 
shown. 
* (3alculated  by Student's t tests,  using groups containing MOP(3  315  cells alone as  controls. 
Groups showing statistically significant  suppression  are italicized. 
:~ Not significant. 
These  experiments  demonstrate  that  two  different  populations  of  Ts  can  be 
experimentally induced that are specific for the idiotypic determinants of a myeloma 
protein and whose effect is to inhibit antibody secretion by the myeloma cells in vitro. 
The  first,  termed  Ysa,  is  generated  by  intravenous  immunization  with  myeloma 
protein-coupled syngeneic splenocytes,  requires  3-4  d  culture with  the myeloma  to 
induce significant  functional suppression,  and is  phenotypically either  Lyt-l+2 + or 
requires Lyt-1 + and Lyt-2  + cells for its terminal maturation. The second type of Ts, 
the effector Ts, can be generated in vivo by subcutaneous immunization with myeloma 
protein-coupled splenocytes, followed by the administration of a soluble extract of Tsl 
cells.  Effector  Ts  inhibit myeloma  function within  1 d,  induce a  greater  degree  of 
suppression  than Tsl, and are phenotypically Lyt-1-2 + T  cells. It is likely that these 
effector  Ts  are  similar  to  the  Lyt-l-2 ÷  idiotype-specific  Ts  induced  by  multiple 
immunizations with myeloma protein in adjuvant (8). The advantage of the protocol 
used in the present experiments is that within the limits of detection it induces only 
Ts and not other idiotype-reactive T cell subsets or anti-idiotypic antibodies. The two 
types  of M315-specific  Ts  described  herein  may  be  related  in one of several  ways. 
First, it is possible that the Tsl population contains cells that expand or mature during 
coculture with the myeloma targets and develop  into effector Ts.  The differences  in 
the Ly phenotypes of the Tsl and effector Ts could be explained by a requirement for 
additional T  cell subsets during the process of expansion or differentiation  in vitro. 1220  ABBAS  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Ly Phenotype of Z$1 and Effector Ts 
T  [ymphocytes  Days of  IgA PFC/  10  ~ MOPC  P*  culture 
315 cells 
mean +. SE 
None  2  303 ::t: 20  -- 
Normal BALB/c  106  2  330 +  38  NS:[: 
Normal BALB/c  2 ×  106  2  411  ±  66  NS 
Effector Ts  106  2  153 ± 23  <0.005 
Effector Ts  2 ×  106  2  60 +.  12  <0.001 
Effector Ts, anti-Lyt-1 +  (2  106  2  176 ±  10  <0.005 
Effector Ts, anti-Lyt-1 +  C  2 ×  106  2  37 ± 8  <0.001 
Effector Ts, anti-Lyt-2 +  C  106  2  433 ±  66  NS 
Effector Ts, anti-Lyt-2 +  C  2 ×  106  2  302 ±  52  NS 
Effector Ts, anti-Thy-1 +  (2  2 ×  106  2  356 ±  41  NS 
Effector Ts, (2  2 ×  106  2  61  ±  17  <0.001 
None  4  263 ±  30  -- 
Normal BALB/c  106  4  359 __. 87  NS 
Tsl  10  s  4  91  ± 28  <0.01 
Tsl, anti-Lyt-I +  (2  106  4  314 ±  49  NS 
Tsl, anti-Lyt-1 +  (2  2 X  106  4  300 +  50  NS 
Ts~, anti-Lyt-2 +  (2  106  4  341  ±. 59  NS 
Tsl, anti-Lyt-2 +  C  2 X  106  4  289 ±  44  NS 
Tsl, anti-Thy-I +  C  2 ×  106  4  220 ±  67  NS 
Tsl, C  106  4  136 +. 33  <0.02 
Ts~, C  2 ×  106  4  133 ± 29  <0.02 
106 MOP(2 315 cells were cultured in triplicate with splenic T  lymphocytes from normal 
BALB/c  mice  or  mice  immunized  to  generate  Tsl  or  effector  Ts,  as  described  in 
Materials and Methods. T  cells were treated as shown, and  106 or 2  ×  106 viable cells 
remaining after treatment were cultured with MOP(2-315 ceils.  Because anti-Thy-l.2 
plus (2 lysed >90% of the T  cells, cultures were done after adjusting treated ceils to the 
initial  lymphocyte concentration  for this  group,  lgA PF(2  were measured by  reverse 
hemolytic plaque assays. Data from one representative experiment out of four are shown. 
Calculated  by  Student's  t  tests,  using  groups  containing  MOPC  315  cells  alone  as 
controls. Groups showing statistically significant suppression are italicized plus comple- 
ment ((2). 
Not significant. 
Alternatively, Tsx may initiate the sequence of complimentary receptor-antireceptor 
interactions  that  culminates  in  the  generation  of effector Ts  (1).  Studies  of the 
suppression  of physiologic immune  responses  have  led  to  the  suggestion  that  TSl 
inhibit  the  inductive or afferent phase of the  response because they only mediate 
suppression when administered at or before the time of immunization (11). However, 
our observations that Tsx manifest a delayed effect, even on myelorna targets that are 
obviously  independent  of inductive  signals,  suggests  that  the  apparent  "afferent 
suppression" of normal  immune responses mediated by Tsl  might  be the result of 
expansion  or  maturation  of these  cells  or  induction  of effector Ts,  which  occurs 
concomitant with the development of the immune response. Such a concept, which 
implies that  Tsa generated with antigen-modified cells in vivo mediate suppression 
not  by  themselves  but  by  developing  into  or  inducing  effector Ts,  is  receiving 
increasing support from several lines of experimental data  (reviewed in ref.  1). The 
ability to induce two cell types at different stages of a  suppressor pathway, and  to 
measure their effects on a  monoclonal, autonomous target, should facilitate analysis 
of the differentiation and mechanisms of action of suppressor T  lymphocytes. 
Summary 
BALB/c  mice  immunized  intravenously  with  syngeneic  splenocytes,  to  which 
affinity-purified IgA produced by the  MOPC  315  myeloma is covalently coupled, ABBAS ET AL.  BRIEF  DEFINITIVE REPORT  1221 
develop suppressor T  cells  (Tsl)  that inhibit  IgA secretion by MOPC  315 cells after 
3-4  d  of co-culture.  Immunization  with  M315-coupled splenocytes subcutaneously, 
followed by administration  of a soluble extract of Tsl cells, leads to the generation of 
effector Ts that  are also idiotype specific and inhibit  myeloma function within  1 d. 
Moreover, effector Ts are Lyt-1-2  ÷, whereas Tsl are either Lyt-1 +2  + or require Lyt-1 + 
and Lyt-2  ÷ cells to mature into effector Ts in vitro. Such a  protocol should be useful 
for analyzing the interactions that result in the maturation of Ts and in defining the 
mechanisms of action of Ts, whose effect can be measured on a  homogeneous target 
population and that are specific for a well-characterized myeloma idiotype. 
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